A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Manish R. Patel, Varun Monga, Shekeab Jauhari, Don Stevens, Lucia Masarova, Meredith McKean, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, Andrew Moore, William Sun, Rachel Chiaverelli, Eric Mintah, Rajneesh Nath, Eytan M. Stein, Neil Palmisiano, Grerk Sutamtewagul, Srdan Verstovsek
Institutions: Florida Cancer Specialists & Research Institute, University of Iowa Hospitals and Clinics, Norton Healthcare, Norton Hospital, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, Prelude Therapeutics Incorporated (United States), Banner Health, Banner MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Thomas Jefferson University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3211718172